Dasiglucagon
Clinical data | |
---|---|
Trade names | Zegalogue |
AHFS/Drugs.com | Zegalogue |
License data |
|
Routes of administration | Subcutaneous |
Drug class | Glucagon receptor agonist |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C152H222N38O50 |
Molar mass | 3381.664 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes.[1][2]
The most common side effects include nausea, vomiting, headache, diarrhea, and injection site pain.[1]
Dasiglucagon was approved for medical use in the United States in March 2021.[1][3][4][5] It was designated an orphan drug in August 2017.[6]
Medical uses[]
Dasiglucagon is indicated for the treatment of severe hypoglycemia in people aged six years of age and older with diabetes.[1][3]
Contraindications[]
Dasiglucagon is contraindicated in people with pheochromocytoma or insulinoma.[1]
References[]
- ^ a b c d e f "Zegalogue- dasiglucagon injection, solution". DailyMed. Retrieved 22 May 2021.
- ^ Li S, Hu Y, Tan X, Wang D, Hu J, Zou P, Wang L (August 2020). "Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes". Expert Opinion on Pharmacotherapy. 21 (11): 1311–1318. doi:10.1080/14656566.2020.1747432. PMID 32267182. S2CID 215405434.
- ^ a b "Dasiglucagon: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 22 March 2021.
- ^ "Zealand Pharma Announces FDA Approval of Zegalogue (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes" (Press release). Zealand Pharma. 22 March 2021. Retrieved 22 March 2021 – via GlobeNewswire.
- ^ Blair HA (June 2021). "Dasiglucagon: First Approval". Drugs. 81 (9): 1115–1120. doi:10.1007/s40265-021-01531-z. PMID 34047955. S2CID 235221008.
- ^ "Dasiglucagon Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 10 August 2017. Retrieved 22 March 2021.
External links[]
- "Dasiglucagon". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03378635 for "A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects" at ClinicalTrials.gov
- Clinical trial number NCT03688711 for "Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM" at ClinicalTrials.gov
- Clinical trial number NCT03667053 for "Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children" at ClinicalTrials.gov
Categories:
- Drugs not assigned an ATC code
- Anti-diabetic drugs
- Orphan drugs
- Gastrointestinal system drug stubs